From :	Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G>
To :	info </o=ExchOrganization/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2069f7f4886b493dbd84f07150d67a52-info>
Subject :	FW: SOF/VEL
Received On :	13.01.2020 13:21
Attachments :	3105355 MyHEP_RG.pdf 3105979 MyHEP ALL.pdf 75067283 - LBST MYHEP ALL 400MG-100MG 28'S A-F EM (V1).pdf 75067284 - CT MYHEP ALL 400MG-100MG 28'S A-F EM (V1).pdf Approved - 75062678 LIT MYHEP ALL 400MG-100MG (24M) A-F EM V1.pdf

გთხოვთ დაარეგისტრიროთ!

From: Ben Kamarck [mailto:Ben.Kamarck@gilead.com]
Sent: 13 January, 2020 17:18
To: Tamar Gabunia ; Ekaterine Adamia
Cc: Graeme Robertson
Subject: RE: SOF/VEL

Dear Dr. Gabunia,

In relation to our commitment to supply sofosbuvir/velpatasvir to the Georgian Ministry of Labour, Health and Social Affairs for its national HCV elimination campaign, Gilead requests the granting of an import permit for 4,003 bottles of MyHEP ALL registered by Mylan in India.

The bottles come from lots 3105355 and 3105979, manufactured in September 2019 with expiration in August 2021. Please see attached certificates of analysis and patient leaflets. Registration with DCGI in India will come separately.

The product will ship in January 2020.

Best regards,

Ben Kamarck

Senior Director, Gilead Global Patient Solutions